TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00243269

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Acupressure expectancy enhancement
Description: This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure expectancy enhancement
Description: This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure expectancy enhancement
Description: This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure expectancy enhancement
Description: This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea.
Study: NCT02873494

Intervention type: DEVICE
Intervention: PHYSIOFLOW - PF05 Lab1TM
Study: NCT03914222

Intervention type: DEVICE
Group type: OTHER
Intervention: CardioSpire (Respirix) Device
Description: Patients will blow into the device through a small tube, which analyzes the signals in the airway patterns.
Study: NCT04126278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Barbotage
Description: Administered as per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Barbotage
Description: Administered as per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg of dexamethasone
Study: NCT02643134

Intervention type: PROCEDURE
Group type: OTHER
Intervention: extracorporeal shockwave lithotripsy
Description: Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).

Intervention type: DEVICE
Group type: OTHER
Intervention: External Physical Vibration Lithecbole
Description: Multi-dimensional physical harmonic vibration inertial guidance technology
Study: NCT02267993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin
Description: Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of \< 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin
Description: Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of \< 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
Study: NCT05546203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: IC was applied over the detected MTrPs and the participant was asked to describe the pressure and pain she felt . It was started with moderate tolerable pressure (7/10) and then severity was increased. The color of the thumb pulp was observed to control the pressure. The pressure was continued for 90 sec. The patient's pain sensation continued to be questioned and the pressure was controlled to a level at comfortable pain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: LLLT was applied for 90 sec at each MTrPs with a frequency of 2000 Hz (3 J) using a GaAs diode laser instrument (Roland Serie Elettronica Pagani, wavelength 904 nm, the frequency range of 5-7000 Hz and maximum peak power of 27, 50 or 2764 W) . The laser probe was held perpendicular to the MTrPs in skin contact without pressure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized exercise program
Description: The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized exercise program
Description: The standardized exercise program included stretching and pilates exercises for core stabilization. All exercises were supervised by the same physiotherapist whom certificated by The Australian Physiotherapy and Pilates Institute (APPI). Pilates exercises were selected from APPI's mat-work exercises and performed in accordance with APPI principles. In addition, patients performed stretching exercises for 5 days a week and pilates exercises for 3 days a week at home.
Study: NCT02999438

Intervention type: DEVICE
Intervention: Actigraph to check activity levels at home

Intervention type: DEVICE
Intervention: Actigraph to check activity levels at home
Study: NCT03622918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colistin and rifampin combination therapy
Description: Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: colistin monotherapy
Description: . Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .
Study: NCT04050202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) Intervention
Description: ABC is a 10 session, home-based, dyadic therapy that is delivered by a trained professional. The sessions focus on improving the parent-child relationship and children's biological and behavioral responses to stress.
Study: NCT03030976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD19-CAR-T cells
Description: A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge \& transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6\~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
Study: NCT03846518

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyrax
Description: Rapid maxillary expansion using the Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars.The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mini Hyrax
Description: Rapid maxillary expansion using the mini Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars. The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
Study: NCT01060280

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on active management
Description: Routine clinical practice plus education on active management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group GDS physiotherapy
Description: Routine clinical practice (which will be substituted by Group GDS) plus education on active management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group GDS physiotherapy
Description: Routine clinical practice (which will be substituted by Group GDS) plus education on active management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual GDS physiotherapy
Description: Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual GDS physiotherapy
Description: Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual GDS physiotherapy
Description: Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
Study: NCT01501877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard smoking cessation intervention
Description: Standard smoking cessation intervention based on clinical practice guidelines.
Study: NCT00481091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Tablet; Oral
Study: NCT02405442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered via subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered via subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered via subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Andecaliximab
Description: Andecaliximab administered via subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match andecaliximab administered via SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match andecaliximab administered via SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match andecaliximab administered via SC injection
Study: NCT01290913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab is an antibody that helps decrease allergic responses in the body
Study: NCT01563653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4 diagnostic tests for surgical success
Description: Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
Study: NCT04623853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable Stiffness AFO
Description: The Dynamic AFO is able to adjust in stiffness depending on activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable Stiffness AFO
Description: The Dynamic AFO is able to adjust in stiffness depending on activity.
Study: NCT00856232

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Air
Description: Compressed medical air

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Medical Oxygen
Study: NCT03565328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
Study: NCT05591313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LI-40
Description: Participants were asked to complete a volume-matched light-intensity exercise for 30-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-30
Description: Participants were asked to complete a volume-matched moderate-intensity exercise for 20-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HI-16
Description: Participants were asked to complete a volume-matched high-intensity exercise for 16-min. The exercise volume was pre-determined based on the energy expenditure (kcal) calculated with 5-min warm-up stage, 20-min main exercise stage (i.e., moderate intensity as 50%-60 % heart rate reserve, HRR), and 5-min cool-down stage.
Study: NCT02730780

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low-Salt Diet
Description: The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low-Salt Diet
Description: The low-salt diet (7 days) will consist of meals, snacks, and sodium free water provided by the study staff.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-Salt Diet
Description: The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High-Salt Diet
Description: The high-salt diet (7 days) consists of each subject's usual diet, supplemented each day with 2 bouillon broth packets, which will be provided to the subject by the study staff.
Study: NCT02384434

Intervention type: DEVICE
Group type: OTHER
Intervention: THOR Laser System for Low Level Laser Therapy (LLLT)
Description: Non-invasive, a cold laser output treatment.
Study: NCT01676779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell therapy
Description: Dendritic cell therapy IV and ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell therapy
Description: Dendritic cell therapy IV and ID
Study: NCT01311024

Intervention type: BIOLOGICAL
Intervention: PCV GSK1024850A
Description: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)

Intervention type: BIOLOGICAL
Intervention: hepatitis B vaccine or hepatitis A vaccine
Description: 2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
Study: NCT05486624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki, one of the complementary treatments, was applied by touching the chakra areas of the body by hand.
Study: NCT03830892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 15 watts, 10 mg nicotine
Description: E-cigarette paired with low nicotine, low device power

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 15 watts, 10 mg nicotine
Description: E-cigarette paired with low nicotine, low device power

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 15 watts, 30 mg nicotine
Description: E-cigarette paired with low nicotine, low device power

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 15 watts, 30 mg nicotine
Description: E-cigarette paired with low nicotine, low device power

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 30 watts, 10 mg nicotine
Description: E-cigarette paired with low nicotine, low device power

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 30 watts, 10 mg nicotine
Description: E-cigarette paired with low nicotine, low device power

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 30 watts, 30 mg nicotine
Description: E-cigarette paired with low nicotine, low device power

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette Lab Session 30 watts, 30 mg nicotine
Description: E-cigarette paired with low nicotine, low device power

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand Session - E-cigarette
Description: E-cigarette paired with own brand liquid and preferred power
Study: NCT04181853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: aerobic exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: aerobic exercise
Study: NCT01855932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Supported
Description: All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
Study: NCT04795609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).
Description: Early mobilization strategy adapted after immediate internal pudendal artery perforator flap reconstruction for abdominoperineal resection (intervention group).~1. Trunk control.~2. Orthostatism.~3. Walk training.~4. Aerobic exercises.~5. Muscle strengthening.
Study: NCT03382548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reducing Antibiotics treatment duration
Description: Antibiotics should be stopped from day 3 to 7 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
Study: NCT03830892

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand Session - E-cigarette
Description: E-cigarette paired with own brand liquid and preferred power

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Own Brand Session - E-cigarette/Cigarette
Description: Own brand cigarette OR E-cigarette paired with own brand liquid and preferred power
Study: NCT03382548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Antibiotics treatment duration
Description: Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 8 days with the exact duration decided by the primary physician.